Fmr LLC Coherus Bio Sciences, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Fmr LLC holds 185,909 shares of CHRS stock, worth $195,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,909

Previous 85,500 117.44%

Holding current value

$195,204

Previous $204,000 57.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.58 - $2.51 $158,646 - $252,026	100,409 Added 117.44%	185,909 $321,000
Q1 2024 May 13, 2024	SELL	$2.02 - $3.14 $152,932 - $237,726	-75,709 Reduced 46.96%	85,500 $204,000
Q4 2023 Feb 13, 2024	BUY	$1.59 - $3.85 $25,990 - $62,932	16,346 Added 11.28%	161,209 $536,000
Q3 2023 Nov 13, 2023	BUY	$3.74 - $5.45 $180,862 - $263,556	48,359 Added 50.11%	144,863 $541,000
Q2 2023 Aug 11, 2023	SELL	$3.79 - $8.3 $5,802 - $12,707	-1,531 Reduced 1.56%	96,504 $412,000
Q1 2023 May 11, 2023	BUY	$5.89 - $10.52 $168,654 - $301,229	28,634 Added 41.26%	98,035 $670,000
Q4 2022 Feb 13, 2023	BUY	$5.69 - $10.07 $130 - $231	23 Added 0.03%	69,401 $549,000
Q3 2022 Nov 10, 2022	BUY	$7.17 - $13.87 $287,151 - $555,479	40,049 Added 136.55%	69,378 $666,000
Q2 2022 Aug 12, 2022	SELL	$5.86 - $13.23 $204,250 - $461,131	-34,855 Reduced 54.3%	29,329 $213,000
Q1 2022 May 13, 2022	BUY	$10.92 - $16.41 $575,276 - $864,495	52,681 Added 457.98%	64,184 $829,000
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $832,080 - $999,443	-52,630 Reduced 82.06%	11,503 $183,000
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $14,366 - $20,156	-1,133 Reduced 1.74%	64,133 $1.03 Million
Q2 2021 Aug 13, 2021	BUY	$12.95 - $15.41 $845,194 - $1.01 Million	65,266 New	65,266 $902,000

Others Institutions Holding CHRS

# of Institutions

143

Shares Held

82.7M

Call Options Held

79.1K

Put Options Held

100K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $81.6M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account